Targeting viruses using a modified sindbis glycoprotein
AssigneeUniversity of Pittsburgh
InventorsIra Bergman, Patricia Whitaker-Dowling
Life of this patent
Estimating the term…
Abstract
The present invention relates to viruses that are engineered to contain a surface ligand molecule which targets the virus to a cell of interest. In particular non-limiting embodiments, the cell of interest is desirably ablated and may be a cancer cell, an infected cell, a cell exhibiting a non-malignant proliferative disorder, or a cell of the immune system. Alternatively, the cell of interest is a target for gene therapy.
Claims20
An isolated recombinant virus comprising (i) a modified surface antigen binding protein associated with viral infectivity, where the modification decreases infectivity of the virus toward a cell that is not a target cell;
- and (ii) a ligand for a receptor present on a target cell, where the ligand is not expressed by native virus.
An isolated recombinant vesicular stomatitis virus comprising (i) a modified surface antigen binding protein associated with viral infectivity, where the modification decreases infectivity of the virus toward a cell that is not a target cell;
- and (ii) a ligand for a receptor that binds to an antigen present on a target cell, where the ligand is not expressed by native virus.
An isolated recombinant vesicular stomatitis virus comprising a Sindbis virus E2 gene modified at amino acid position 55.
An isolated recombinant vesicular stomatitis virus comprising a Sindbis virus E2 gene modified at amino acid position 246.
A method of destroying a target cell, comprising exposing the target cell to a lytic amount of a recombinant virus comprising (i) a modified surface antigen binding protein associated with viral infectivity, where the modification decreases infectivity of the virus toward a cell that is not a target cell;
- and (ii) a ligand for a receptor present on a target cell, where the ligand is not expressed by native virus.
A method of destroying a target cell, comprising exposing the target cell to a lytic amount of a recombinant vesicular stomatis virus comprising (i) a modified surface antigen binding protein associated with viral infectivity, where the modification decreases infectivity of the virus toward a cell that is not a target cell;
- and (ii) a ligand for a receptor that binds to an antigen present on a target cell, where the ligand is not expressed by native virus.
Dependencies are inferred from the claim text.